Clinical trials: Chronic Pulmonary Obstruction
Pulmonary Disease, Chronic Obstructive
Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this trial was to establish non-inferiority of lung function response to 25 μg salmeterol, administered as the xinafoate salt, in an inhalation powder delivered from hard polyethylene (PE) capsules via…
- Trial name
- NCT02242227
- Testing
- Salmeterol xinafoate, Serevent® Diskus®
- Volunteers
- 111 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)
The inflammation associated with COPD is characterized by a prominent infiltration of neutrophils in lung tissue and airways. The CXC chemokine receptor type 2 (CXCR2) plays a pivotal role in neutrophil recruitment to the lungs…
- Trial name
- NCT03250689
- Testing
- Danirixin, Rescue medication, Inhaled COPD maintenance medication
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Study to Evaluate Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to determine whether inhalation of Bimosiamose is safe and effective in the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01108913
- Testing
- Bimosiamose
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Revotar Biopharmaceuticals AG
Chronic Obstructive Pulmonary Disease
Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity
This study compared the effects of a single dose of indacaterol with that of a single dose of tiotropium on inspiratory capacity.
- Trial name
- NCT00999908
- Testing
- Indacaterol 150 μg, Tiotropium 18 μg
- Where
- 11 sites in Italy
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils
The purpose of this study is to investigate lung function parameters, composite endpoint for exacerbations in chronic obstructive pulmonary disease (COPDCompEx), symptoms and to provide safety information after tozorakimab or…
- Trial name
- COMETA (NCT06897748)
- Testing
- Tozorakimab
- Where
- 12 sites in Russia
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease
The purpose of this study is to determine the triple combination of beclometasone dipropionate+Formoterol fumarate+Glycopyrrolate bromide is effective for the treatment of severe COPD patients (chronic obstructive pulmonary…
- Trial name
- NCT01911364
- Testing
- BDP/FF/GB, Tiotropium, BDP/FF + Tiotropium
- Where
- 3 sites in Germany, Hungary and 1 more
- Volunteers
- 3,686 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease (COPD)
Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation
The purpose of this study is to evaluate the safety of Targeted Lung Denervation Therapy (or TLD TherapyTM) in patients suffering from COPD.
- Trial name
- IPS-I (NCT01483534)
- Testing
- TLD Therapy (IPS SystemTM)
- Where
- 3 sites in Netherlands, South Africa
- Volunteers
- 22 people
- Sponsor
- Nuvaira, Inc.
Chronic Obstructive Pulmonary Disease COPD
Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871
This is a study to evaluate the effects of AZD8871 in patients with COPD. Adult male or female patients with moderate to severe COPD, who agree to be in this study, will receive 3 treatments, i.e.
- Trial name
- NCT02971293
- Testing
- AZD8871 100 µg, AZD8871 600 µg
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence
This study was evaluating the effect of reminder notifications and motivational/adaptive messages on treatment adherence behavior in subjects with COPD.
- Trial name
- ADVICE (NCT03379233)
- Testing
- Concept2 inhaler, Concept2 inhaler with patient application
- Where
- 9 sites in Germany, Netherlands
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Advanced Immunological Approach in COPD Exacerbation
Chronic obstructive pulmonary disease (COPD) are characterized by frequent relapses, often resulting from common bacterial infections. Enhancing the immune response in these patients may decrease the frequency of these relapses.
- Trial name
- AIACE (NCT02417649)
- Testing
- Ismigen
- Where
- 13 sites in Italy
- Volunteers
- 288 people
- Sponsor
- Lallemand Pharma AG
Pulmonary Disease, Chronic Obstructive
Ipratropium Bromide in Peri-Operative COPD
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-centre trial.The trial aims to evaluate efficacy of nebulized ipratropium bromide in Chinese peri-operative patients with COPD under general…
- Trial name
- NCT01943552
- Testing
- ipratropium bromide
- Where
- 9 sites in China
- Volunteers
- 192 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
The purpose of this study is to compare the efficacy and safety of BCT197 when added on to standard of care in adult subjects with acute respiratory exacerbations of chronic obstructive pulmonary disease requiring…
- Trial name
- NCT02700919
- Testing
- BCT197
- Where
- 46 sites in United States, Bulgaria and 8 more
- Volunteers
- 282 people
- Sponsor
- Mereo BioPharma
Pulmonary Emphysema
Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation
The purpose of this study is to evaluate the safety and efficacy of the Aeris BLVR System in patients with advanced emphysema.
- Trial name
- NCT00205907
- Testing
- BLVR Hydrogel
- Where
- Israel
- Volunteers
- 4 people
- Sponsor
- Aeris Therapeutics
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Airways Disease
To obtain further information on the tolerability of Atrovent® inhalets in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice
- Trial name
- NCT02238132
- Testing
- ATROVENT® inhalets
- Volunteers
- 374 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
The Efficacy and Safety of Erdosteine in Chronic Obstructive Pulmonary Disease (COPD)
The aim of the study is to evaluate the effect of erdosteine, compared to placebo, on exacerbation rate over a 12-month treatment period in patients with moderate-to-severe COPD.
- Trial name
- RESTORE (NCT01032304)
- Testing
- Erdosteine
- Where
- 46 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 492 people
- Sponsor
- Edmond Pharma
Chronic Obstructive Pulmonary Disease
REported Outcomes in COPD With Trixeo in Real worlD in Germany
Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms (including breathlessness, cough, and sputum production), which has a substantial impact on health-related quality of life (HRQoL).
- Trial name
- RECORD (NCT05311306)
- Where
- 62 sites in Germany
- Volunteers
- 475 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to estimate the comparative bronchodilator effect size and variability for tiotropium (Spiriva, 18 µg q.d.) with the free combination of salmeterol (Serevent, 50 µg b.i.d.) and fluticasone…
- Trial name
- NCT00239499
- Testing
- Tiotropium, Salmeterol plus Fluticasone
- Where
- 12 sites in South Africa
- Volunteers
- 107 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population
The purpose of this study is to evaluate the pharmacodynamics (bronchodilation) of single doses of inhaled LAS100977 in COPD patients.
- Trial name
- NCT01425814
- Testing
- LAS100977, Reference
- Where
- 8 sites in Germany
- Volunteers
- 87 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients
Patients with Chronic Obstructive Pulmonary Disease (COPD) suffer from frequent and recurrent acute exacerbations (AECB) which are associated with enormous healthcare expenditures and significant morbidity, specifically an…
- Trial name
- NCT00739648
- Testing
- MP-376
- Where
- 39 sites in United States
- Volunteers
- 322 people
- Sponsor
- Amgen
COPD (Chronic Obstructive Pulmonary Disease)
Phase 1 PK Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
This is a phase 1, single-dose, 2-period crossover study in healthy volunteers to compare the systemic pharmacokinetic (PK) profile of inhaled AERO-002 versus inhaled active comparator product.
- Trial name
- NCT07802730
- Testing
- AERO-002 (60 mcg), Glycopyrrolate (18 mcg)
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AeroRx Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.